Your session is about to expire
← Back to Search
Computer Algorithm
Claims-based Algorithm for Amyloidosis
N/A
Waitlist Available
Led By Edward Miller, MD
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
Study Summary
This trial will test how well a new algorithm can identify patients with ATTR amyloidosis, a disease where abnormal proteins build up in organs.
Who is the study for?
This trial is for patients within the YNHHS claims dataset who are flagged by a computer algorithm as potentially having ATTR amyloidosis, which includes both hereditary and non-hereditary forms. They must be willing to undergo further clinical evaluation. Pregnant individuals or those opting out of research in the Epic system cannot participate.Check my eligibility
What is being tested?
The study is testing the effectiveness of a computer algorithm designed to identify patients at risk of ATTR amyloidosis using medical records data. The goal is to see how well this algorithm predicts actual cases when compared with Yale's list of potential subjects.See study design
What are the potential side effects?
Since this trial involves an evaluation process using a computer algorithm rather than medication, there are no direct side effects from interventions like you would expect with drug trials.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Diagnostic performance of algorithm in identifying patients with ATTR amyloidosis
Secondary outcome measures
Proportion of diagnosed patients
Trial Design
1Treatment groups
Experimental Treatment
Group I: Computer algorithm for ATTRExperimental Treatment1 Intervention
Patients will be evaluated for the identification of ATTR Amyloidosis through a claims-based algorithm
Find a Location
Who is running the clinical trial?
Yale UniversityLead Sponsor
1,847 Previous Clinical Trials
2,737,568 Total Patients Enrolled
1 Trials studying Amyloidosis
800 Patients Enrolled for Amyloidosis
Alnylam Pharmaceuticals IncUNKNOWN
Edward Miller, MDPrincipal InvestigatorYale University
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have been identified as having ATTR amyloidosis by a specific diagnostic algorithm.I need further tests to confirm if I have ATTR amyloidosis.I have not opted out of research in the Epic system.I am at risk for ATTR and am being treated within the YNHHS system.
Research Study Groups:
This trial has the following groups:- Group 1: Computer algorithm for ATTR
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger